Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -159.06% is 51% above its 3-year average of -325.58%, near the high end of its 3-year range (-514.20%–-159.06%).
31.25% above its 12-month average of -231.35%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -168.02%.
EBITDA MARGIN
-159.06%
EBITDA MARGIN AVG TTM
-231.35%
EBITDA MARGIN AVG 3Y
-311.41%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+31.25%
CURRENT VS 3Y AVG
+48.92%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
20/20 Biolabs Inc.
Market Cap
$4.32M
EBITDA Margin
-159.06%
TTM Avg
-231.35%
3Y Avg
-311.41%
5Y Avg
N/A
Market Cap
$4.41M
EBITDA Margin
-2411.68%
TTM Avg
-15920.55%
3Y Avg
-15920.55%
5Y Avg
-10610.40%
Market Cap
$4.42M
EBITDA Margin
-445.85%
TTM Avg
-1797.00%
3Y Avg
-2252.67%
5Y Avg
-1514.30%
Market Cap
$4.18M
EBITDA Margin
-1456.00%
TTM Avg
-1456.00%
3Y Avg
-1456.00%
5Y Avg
-1456.00%
Market Cap
$3.94M
EBITDA Margin
-890.82%
TTM Avg
-527.81%
3Y Avg
-554.45%
5Y Avg
-445.87%
Market Cap
$4.79M
EBITDA Margin
-1127.44%
TTM Avg
-14514.89%
3Y Avg
-11694.21%
5Y Avg
-11694.21%
Market Cap
$4.96M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 20/20 Biolabs Inc. (AIDX) | $4.32M | -159.06% | -231.35% | -311.41% | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | -2411.68% | -15920.55% | -15920.55% | -10610.40% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | -445.85% | -1797.00% | -2252.67% | -1514.30% |
| GRI Bio, Inc. (GRI)vs › | $4.18M | -1456.00% | -1456.00% | -1456.00% | -1456.00% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.94M | -890.82% | -527.81% | -554.45% | -445.87% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | -1127.44% | -14514.89% | -11694.21% | -11694.21% |
| CalciMedica, Inc. (CALC)vs › | $4.85M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | -8.85% | 9.13% | 18.32% | 18.32% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
Gross Margin
31.5%
EBITDA Margin
-159.1%
Operating Margin
-162.9%
Net Margin
-285.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -168.02% |
| 2026-03-31 | -404.26% |
| 2025-12-31 | -166.27% |
| 2025-09-30 | -186.84% |
| 2024-12-31 | -226.16% |
| 2024-09-30 | -514.20% |
| 2023-06-30 | -514.14% |
| 2023-03-31 | -424.79% |
